Valued at USD 569.90 million in 2025, the global viral vector bioanalytical testing services market is projected to reach USD 649.07 million in 2026 and USD 1,877.41 million by 2034, growing at a CAGR of 14.2% during the forecast period 2026–2034. While AAV vectors and safety testing lead today, the fastest-growing segments point to efficacy validation, cell-based therapies, and digital laboratories. This article outlines those growth areas for B2B stakeholders in the viral vector bioanalytical testing services market.

Potency Assays Gain Importance

The potency assay services segment is projected to register the fastest CAGR among service types, at nearly 13.58% during the forecast period, owing to increasing focus on therapeutic efficacy validation and advanced characterization of viral vector products. Rising demand for cell-based analytical assays continues to support segment growth across oncology and gene editing applications. Potency assays sit alongside safety and purity testing, which accounted for approximately 38.74% of the market in 2025. Potency testing is one of the services listed in the report's segmentation alongside stability testing, identity testing, and replication competency testing.

Lentiviral Vectors and Cell-Based Therapies

The lentiviral vectors segment is projected to grow at the fastest CAGR among vector types, driven by rising commercialization of CAR-T therapies and ex vivo gene therapies. Increasing biosafety testing requirements continue to support demand for lentiviral analytical services. The segmentation also covers adenoviral, retroviral, and other viral vectors.

Browse Insights:

https://www.polarismarketresearch.com/industry-analysis/viral-vector-bioanalytical-testing-services-market

Cell therapy and vaccine development are listed alongside gene therapy, oncology, and rare diseases among applications. Advances in gene-editing technology and multi-modal therapies are driving demand for sophisticated testing solutions, and the continued development of CRISPR therapy and next-generation biologics is shaping service offerings.

Oncology Applications

By application, the oncology segment is projected to grow at the fastest CAGR owing to development of CAR-T therapies and precision medicine solutions. Pharmaceutical companies continue to expand oncology-focused gene therapy pipelines across global markets. The WHO reported approximately 10 million cancer deaths globally in 2022, a burden that underpins investment in oncology programs and the analytical validations they require. Oncology is listed among applications alongside gene therapy, cell therapy, rare diseases, and vaccine development.

AI and Laboratory Automation

AI-driven bioanalytical platforms are creating significant opportunities. AI-enabled laboratory automation is becoming popular in GMP laboratories to improve testing accuracy and streamline work, and biotech firms are adopting predictive analytics and automated quality control to enhance viral vector characterization and batch analysis. In January 2026, Elucidata launched AI Labs to develop AI-driven biomedical research solutions focused on real-world data analysis and drug discovery. Companies are increasingly integrating machine learning tools for batch analysis and predictive quality management software. The report also expects continued emphasis on end-to-end outsourcing, and describes innovations in AI-enabled analytical tools and automation, along with developments in precision medicine, as drivers of future growth.

Competitive Landscape and Expansion

The viral vector bioanalytical testing services market is moderately consolidated, with specialized CROs, CDMOs, and analytical laboratories competing on analytical accuracy, regulatory compliance expertise, turnaround time, and global laboratory capabilities. Key players include BioAgilytix, Catalent, Charles River Laboratories, Eurofins Scientific, Intertek Group plc, Laboratory Corporation of America Holdings, Merck KGaA, Pace Analytical Services, Sartorius AG, SGS SA, Thermo Fisher Scientific, and WuXi AppTec. In April 2026, ProBio CDMO expanded viral vector development services with a new packaging test platform at its Hopewell, US site. North America held 44.37% of the market in 2025, while Asia Pacific is projected to grow fastest; the 14.2% CAGR signals continued investment in analytical capacity. Competition factors include analytical accuracy, regulatory compliance expertise, testing turnaround time, and global laboratory capabilities, and leading CROs and CDMOs are buying analytical laboratories to gain expertise and expand geographically. North America continues to see strong investment in laboratory expansion and viral vector manufacturing infrastructure, which supports testing demand.

More Trending Latest Reports By Polaris Market Research:

airlines-market

silent-luxury-goods-market

global-hypertension-drug-market

nuclear-power-plant-control-system-market

ocean-economy-market

durable-medical-equipment-market

comparator-drug-sourcing-market

dental-equipment-market

multiomics-market